An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

October 31, 2006

Conditions
Conscious Sedation
Interventions
DRUG

AQUAVAN® (fospropofol disodium) Injection

DRUG

Midazolam HCI

Trial Locations (20)

10021

Research Associates of New York (New York Gastroenterology Associates), New York

20678

Shah Associates, Prince Frederick

20707

Maryland Digestive Diseases Center, Laurel

20815

Chevy Chase Clinical Research, Chevy Chase

28801

Asheville Gastroenterology Associates, Asheville

32256

Borland-Groover Clinic, Jacksonville

35801

Clinical Research Associates, Huntsville

37203

Gastrointestinal Institute, Nashville

38138

Memphis Gastroenterology Group, PC, Germantown

39202

Gastrointestinal Associates, PA, Jackson

46202

Indiana University Medical Center/Clarian Health Partner, Indianapolis

47713

Welborn Clinic, Evansville

48067

Oakland Colon & Rectal Associates, Royal Oak

48098

Center for Digestive Health, Troy

53215

Wisconsin Center for Advance Research, Milwaukee

61107

Rockford Gastroenterology Associates, Rockford

78215

Alamo Research Center, San Antonio

93702

UCSF-Fresno/University Medical Center, Fresno

97225

WestHills Gastroenterology Associates, Portland

99204

Spokane Digestive Disease Center, Spokane

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00261599 - An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy | Biotech Hunter | Biotech Hunter